Author

Josephine A. Adattini

Observed names: Josephine A. Touma, Josephine Adattini

Institution: Cancer Institute of New South Wales

Observed institutions: The University of Sydney, Cancer Institute of New South Wales, Clinical Excellence Commission

ORCID: 0000-0002-2575-7910

Observed ORCID: 0000-0002-2575-7910

OpenAlex ID: A5016383305

The role of ethnicity in personalized dosing of small molecule tyrosine kinase inhibitors used in oncology

2017 · Josephine A. Touma, Andrew J. McLachlan, et al. · Translational Cancer Research · 42

Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice

2025 · Geeta Sandhu, Josephine Adattini, et al. · EClinicalMedicine · 16

Real‐world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience

2022 · Josephine A. Adattini, Annette S. Gross, et al. · Pharmacology Research & Perspectives · 13

Aligning kidney function assessment in patients with cancer to global practices in internal medicine

2025 · Geeta Sandhu, Josephine Adattini, et al. · EClinicalMedicine · 8

International consensus guideline for anticancer drug dosing in kidney dysfunction (ADDIKD): A standardized approach to assessing kidney function in cancer patients and its application to anticancer drug dosing.

2022 · Geeta Sandhu, Josephine Adattini, et al. · Journal of Clinical Oncology · 7

A methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney function

2025 · Geeta Sandhu, Evangeline Armstrong Gordon, et al. · EClinicalMedicine · 5

Melatonin: A Review of the Evidence for Use in Hospital Settings

2025 · Josephine A. Adattini, Carly Wills, et al. · Pharmacology Research & Perspectives · 5

Application of physiologically based pharmacokinetic modeling to understand real‐world outcomes in patients receiving imatinib for chronic myeloid leukemia

2023 · Josephine A. Adattini, Jeffry Adiwidjaja, et al. · Pharmacology Research & Perspectives · 5

Insights into dasatinib use and outcomes in real-world patients with chronic myeloid leukemia

2023 · Josephine A. Adattini, Annette S. Gross, et al. · Haematologica · 2

Physiologically Based Pharmacokinetic Modeling Approaches for Patients With SARS‐CoV‐2 Infection: A Case Study With Imatinib

2022 · Jeffry Adiwidjaja, Josephine A. Adattini, et al. · The Journal of Clinical Pharmacology · 2

Corrigendum to “A methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney function”

2026 · Geeta Sandhu, Evangeline Armstrong Gordon, et al. · EClinicalMedicine

Works count: 11

Citation count: 105

H-index: 5

I10-index: 3